Image Credit: STAT News
STAT+: Cancer therapy’s new ‘gold rush’: bispecific antibodies that hit key combination of targets
Recent results raise hope of new "broad, pan-tumor platform" like Keytruda. The emerging drugs are bispecific antibodies that bind to a key pair of proteins.